Ken Wood

Ken is vice president, early development, overseeing early development program leadership, medical writing, clinical pharmacology and clinical project management. Ken joined Forma in 2017 as senior director, development project leadership. His contributions are evident throughout Forma’s pipeline, including leadership of the team that discovered and advanced FT-7051 to IND-enabling studies, the clinical development team that planned and initiated etavopivat registrational and life cycle clinical studies, and oversight of companion diagnostic IVD development for selection and treatment of patients with AML with olutasidenib. Ken has more than 20 years of experience in the biotech industry ranging from early drug discovery through late-stage clinical development, contributing to multiple INDs and to the development of several approved therapies. Prior to joining Forma, Ken served as director, diagnostics and biomarkers at Seattle Genetics, where he was responsible for clinical biomarker and patient selection strategies and companion diagnostic IVD development. Earlier in his career, Ken held group and program leadership positions at Array Biopharma and at Cytokinetics. Ken earned a Bachelor of Science degree in biology from Tufts University and a Ph.D. in cell and developmental biology from Harvard University, followed by a Damon Runyon-Walter Winchell post-doctoral fellowship at Johns Hopkins University and the Ludwig Institute for Cancer Research, UC San Diego.